Redeye gives a short comment on the Q1 report from Acarix. Both the sales and the EBIT figures were largely in line with our expectations and we reiterate our Base case of SEK 1.5 per share following the report. Important events ahead are FDA response on the de novo application for the CADScor system and a decision from G-BA regarding reimbursement for the public German market (expected mid-year).